NXXI (C/W MicroCap promo) earnings, etc:
( see during April 2007 C/W promo that contains Green light means GO )
05/14/07 NXXI Results : Third Quarter of Fiscal 2007
biz.yahoo.com
includes, but not limited to :
...two new customers, Ross/Abbott for its Glucerna line of products, the #1 diabetes brand in the US;
and Coca Cola, Inc. for its new Minute Maid Multi Formulation....
Ross/Abbott's Glucerna
glucerna.com
Minute Maid Multi Formulation :
(I'm not sure if this is the product that is mentioned in NXXI news release, but it does have Chromium to help maintain normal blood glucose levels. Minute Maid may be using NXXI's Chromax --- chromium picolinate --- )
minutemaid.com
NXXI C/W site search ( advanced and time period of one year )
NXXI appears to have been first introduced to MicroCap subscribers on 12/12/2006 in "A Double-Play on Diabetes and Cardio Health", but there was a March 2004 item, "Spotting Microcap ChangeWaves - Know Your Risk Levels" that might have contained a mention of NXXi. --- AND --- NXXI appears to have been introduced to InnerCircle subscribers on 01/26/2007 in a "ChangeWave Inner Circle Briefing" and mentioned again on 02/02/07 and 03/02/07. These would have been before the April 2007 C/W promo.
I still wonder if the timing of the promos are to give the MicroCap and InnerCircle subscribers an opportunity to exit the position. However, the most recent comments re NXXI are after the April promo
05/08/2007 Living It Up With Bioscience Microcap
05/01/2007 Managing Microcap Risk Microcap
NXXI: 6 month chart
--- Look for volume and share price spikes on 12/12/2006 and 01/26/2007 ---
bigcharts.marketwatch.com
Quotes for NXXI and competitors:
finance.yahoo.com
--------------------------------------------------------------------------------
Nutrition 21 Reports Results for the Third Quarter of Fiscal 2007
part of the news release with financials is:
Paul Intlekofer, president and CEO of Nutrition 21, said, "We completed our third consecutive quarter of significant increases in revenue and in the third quarter, we improved our bottom line when compared to the first and second quarters. We are beginning to realize the efforts of our retail sales staff, our direct response capabilities and the consumer demand for our products that address obesity/pre-diabetes, diabetes, cardiovascular health, and arthritis/joint health."
"During and after the quarter we made progress on the following fronts:
* Our ingredients division experienced an increase in quarter-to quarter sales in fiscal 2007 partially as a result of securing two new customers, Ross/Abbott for its Glucerna® line of products, the #1 diabetes brand in the US; and Coca Cola, Inc. for its new Minute Maid® Multi Formulation. This increase in quarter-to quarter sales further confirms the importance of Chromax® chromium picolinate and validates both our research efforts and awareness campaigns.
* Chromax is beginning to establish itself in the market as the natural solution for addressing "Blood Sugar Health," which we believe is of importance in view of the increase in obesity and the growing number of people with diabetes. We continue to run national radio spots supporting Chromax's continued sales growth. We also completed and tested a 30-minute infomercial that we expect will further support Chromax sales. During its last plan-o-gram cycle CVS/pharmacy added shelf facing and improved Chromax's shelf positioning.
* We were able to quickly leverage our retail sales capabilities to gain national distribution for both Iceland Health® Maximum Strength Omega-3 and Iceland Health® Joint Relief products. We began shipments to a few retailers in March and are on schedule to have national distribution at the major food, drug and mass retailers by the end of June, including Wal-Mart, CVS/pharmacy, Walgreens, Duane Reade, Krogers, Rite Aid and other retailers. The Iceland Health retail launch is being supported by substantial TV, radio and print media initiatives. The Omega-3 category in general is enjoying a large volume of third party endorsements and news stories on its numerous health benefits.
* We are timing the retail expansion of Diachrome® supplements beyond CVS/pharmacy and Walgreens with the publication of our 447-subject randomized, double-blind, placebo-controlled study on Diachrome for people with diabetes, which is expected in the next few months.
* Our direct response sales continue to be strong. We are also leveraging the media spends from this division to support our retail initiatives.
* We have retained our assigned shelf space for our products across our retail distribution outlets and are continuing to work with the retailers to increase and/or improve our positioning."
Mr. Intlekofer concluded, "We are pleased with the sales momentum we have generated and believe that our sales will increase significantly in fiscal year 2008." |
